Medicine details

ImageAmimax 500
NameAmimax 500
DosageInjection
Generic NameAmikacin
Classes Antiinfective Agent
Antibiotic
Aminoglycoside
Diseases Infectious Disease
Meningitis
Neonatal Sepsis
Pneumonia
UTI (Urinary Tract Infection)
CompanyBio Pharma Ltd.

Drug Package Details

Strength500 mg/2 ml
Storage Condition
Origin CountryBangladesh
Commercial Pack10
Price per pack478.17
Cost per pack420.79
Package unit2 ml amp
Price per unit47.82
Cost per unit42.08
Discount0
Coupon
Remarks

Amikacin

Amikacin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in bacteria that are susceptible to it. In vitro, it is bactericidal against both Gram-positive and Gram-negative bacteria.

  • Amikacin Injection is used to treat serious infections caused by susceptible strains of Gram-negative bacteria in the short term.
  • The main Gram-positive organism susceptible to amikacin is Staphylococcus aureus, including methicillin-resistant strains.
  • Amikacin should only be used as a last resort in the treatment of staphylococcal infections, and only in patients with severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.
  • Amikacin Injection is used to treat neonatal sepsis when other aminoglycosides cannot be used due to sensitivity testing.
  • Because of the possibility of Gram-positive organisms such as streptococci or pneumococci infections, concomitant therapy with a penicillin type drug may be indicated in certain severe infections such as neonatal sepsis. If a penicillin-type drug is required, the drugs should be administered separately and at different sites because in-vitro mixing of the two drugs causes amikacin inactivation.
  • When caused by susceptible organisms, clinical studies have shown that amikacin is effective in treating bacteremia, septicemia, including neonatal sepsis, and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, post-operative infections, and complicated and recurrent urinary tract infections.
  • Adults and Children: The usual recommended dose of amikacin is 15mg/kg daily given in two or three equally divided doses. Neonates and
  • Premature Infants: Patients with normal renal function are given a lower dose. Begin treatment with a 10 mg/kg loading dose, followed by 7.5 mg/kg every 12 hours. The total daily dose should not be more than 15 mg/kg. I.V. solution infusions should be given over a 1 to 2 hour period.
  • Impaired Renal Function: In patients with impaired renal function, either the dose or the dosage interval needs to be adjusted to avoid accumulation.

Common side effects associated with IV amikacin include-

  • Hearing loss
  • Azotemia
  • Renal function abnormality
  • Pain at injection site
  • Tinnitus
  • Vertigo
  • Dizziness
  • Eosinophilia
  • Arthralgia
  • Cross allergenicity: There is evidence of cross allergenicity among aminoglycosides. As a result, patients who have previously demonstrated hypersensitivity to this class of drugs should proceed with caution.
  • Nephrotoxicity: Amikacin sulfate, like other aminoglycosides, has the potential to be nephrotoxic and neurotoxic; therefore, dosage precautions and adequate hydration should be taken. Renal function should be closely monitored in patients who have known or suspected renal impairment (e.g., decreased glomerular filtration), as well as in those who have initially normal renal function but develop signs of renal dysfunction during therapy.
  • Ototoxicity: Ototoxicity, both auditory and vestibular, can occur in patients treated at higher doses or for longer periods of time than recommended. Patients with kidney disease are at the greatest risk of developing amikacin-induced ototoxicity. Aminoglycoside induced ototoxicity is usually irreversible
  • Neurotoxicity: Amikacin (188mg/kg) has been shown to cause muscular paralysis and neuromuscular blockade in cats. When amikacin is combined with neuromuscular blocking drugs or anesthetics, the possibility of respiratory paralysis and neuromuscular blockade should be considered.
  • Superinfection: If overgrowth of non-susceptible organisms occurs, appropriate therapy should be initiated.  

 

Contraindication

 Amikacin Injection is contraindicated in patients with a known history of hypersensitivity to amikacin, any constituents of the injection.

Amikacin is contraindicated in-

  • Myasthenia gravis
  • Pregnancy
  • Lactation
  • Severe renal problems